Here’s my latest video about arguably the most debated biomarker, LDL!
LDL is arguably the most debated biomarker in terms of what’s optimal for health. In the video, I present data showing that 100 — 140, not 50 — 70 mg/dL may be optimal in terms of minimizing disease risk and maximizing longevity.
A bit of everything here from hallmarks of aging to epigenetic reprogramming(which effects telomeres, gene expression, etc) and even diet.
In this talk given at Ending Age-Related Diseases 2020, Dr. Kris Verburgh of the Free University of Brussels discusses the methods by which people might lead longer, healthier lives. While some of these methods involve the use of advanced rejuvenation biotechnology techniques, others are simpler to implement and require a minimum amount of technology, such as nutrition and exercise, along with health-monitoring technology that already exists in the public space.
Continue reading “Kris Verburgh | How to Live Longer? High-Tech and Low-Tech Approaches” »
For years, futurists have attempted to predict when, in the future, we will finally achieve the technological singularity’’ — a technological breakthrough so profound, it changes the course of humanity. Specifically, futurists have been talking about the moment when super-human artificial intelligence becomes reality. Or — to put it simply — when computers become smarter than people.
However, at Centaura, we believe that the world needs to prepare for a different singularity — one that might arrive even before super-human intelligence. It’s the moment when humans have the power to slow down — and even reverse aging.
The idea of the singularity first became popular nearly thirty years ago by the science fiction writer Vernor Vinge. In his essay The Coming Technological Singularity, he famously declared, Within thirty years, we will have the technological means to create superhuman intelligence. Shortly after, the human era will be ended.
Andres de Tenyi.
Yuri Deigin, MBA is a serial biotech entrepreneur, longevity research evangelist and activist, and a cryonics advocate. He is an expert in drug development and venture investments in biotechnology and pharmaceuticals. He is the CEO at Youthereum Genetics and the Vice President at Science for Life Extension Research Support Foundation.
http://youthereum.ca/
I just read an incredible post about Transhumanism by Francesco Neo Amati, CM of Transhumanism: The Future of Humanity.
What an excellent representation of how pragmatic and collaborative our community can be. People like Francesco Neo Amati are the reason why I call myself a Transhumanist…
“Community Announcement:
Takeaways * Scientists have made progress growing human liver in the lab. * The challenge has been to direct stems cells to grow into a mature, functioning adult organ. * This study shows that stem cells can be programmed, using genetic engineering, to grow from immature cells into mature tissue. * When a tiny lab-grown liver was transplanted into mice with liver disease, it extended the lives of the sick animals.* * *Imagine if researchers could program stem cells, which have the potential to grow into all cell types in the body, so that they could generate an entire human organ. This would allow scientists to manufacture tissues for testing drugs and reduce the demand for transplant organs by having new ones grown directly from a patient’s cells. I’m a researcher working in this new field – called synthetic biology – focused on creating new biological parts and redesigning existing biological systems. In a new paper, my colleagues and I showed progress in one of the key challenges with lab-grown organs – figuring out the genes necessary to produce the variety of mature cells needed to construct a functioning liver. Induced pluripotent stem cells, a subgroup of stem cells, are capable of producing cells that can build entire organs in the human body. But they can do this job only if they receive the right quantity of growth signals at the right time from their environment. If this happens, they eventually give rise to different cell types that can assemble and mature in the form of human organs and tissues. The tissues researchers generate from pluripotent stem cells can provide a unique source for personalized medicine from transplantation to novel drug discovery. But unfortunately, synthetic tissues from stem cells are not always suitable for transplant or drug testing because they contain unwanted cells from other tissues, or lack the tissue maturity and a complete network of blood vessels necessary for bringing oxygen and nutrients needed to nurture an organ. That is why having a framework to assess whether these lab-grown cells and tissues are doing their job, and how to make them more like human organs, is critical. Inspired by this challenge, I was determined to establish a synthetic biology method to read and write, or program, tissue development. I am trying to do this using the genetic language of stem cells, similar to what is used by nature to form human organs. Tissues and organs made by genetic designsI am a researcher specializing in synthetic biology and biological engineering at the Pittsburgh Liver Research Center and McGowan Institute for Regenerative Medicine, where the goals are to use engineering approaches to analyze and build novel biological systems and solve human health problems. My lab combines synthetic biology and regenerative medicine in a new field that strives to replace, regrow or repair diseased organs or tissues. I chose to focus on growing new human livers because this organ is vital for controlling most levels of chemicals – like proteins or sugar – in the blood. The liver also breaks down harmful chemicals and metabolizes many drugs in our body. But the liver tissue is also vulnerable and can be damaged and destroyed by many diseases, such as hepatitis or fatty liver disease. There is a shortage of donor organs, which limits liver transplantation. To make synthetic organs and tissues, scientists need to be able to control stem cells so that they can form into different types of cells, such as liver cells and blood vessel cells. The goal is to mature these stem cells into miniorgans, or organoids, containing blood vessels and the correct adult cell types that would be found in a natural organ. One way to orchestrate maturation of synthetic tissues is to determine the list of genes needed to induce a group of stem cells to grow, mature and evolve into a complete and functioning organ. To derive this list I worked with Patrick Cahan and Samira Kiani to first use computational analysis to identify genes involved in transforming a group of stem cells into a mature functioning liver. Then our team led by two of my students – Jeremy Velazquez and Ryan LeGraw – used genetic engineering to alter specific genes we had identified and used them to help build and mature human liver tissues from stem cells. The tissue is grown from a layer of genetically engineered stem cells in a petri dish. The function of genetic programs together with nutrients is to orchestrate formation of liver organoids over the course of 15 to 17 days. Liver in a dishI and my colleagues first compared the active genes in fetal liver organoids we had grown in the lab with those in adult human livers using a computational analysis to get a list of genes needed for driving fetal liver organoids to mature into adult organs. We then used genetic engineering to tweak genes – and the resulting proteins – that the stem cells needed to mature further toward an adult liver. In the course of about 17 days we generated tiny – several millimeters in width – but more mature liver tissues with a range of cells typically found in livers in the third trimester of human pregnancies. Like a mature human liver, these synthetic livers were able to store, synthesize and metabolize nutrients. Though our lab-grown livers were small, we are hopeful that we can scale them up in the future. While they share many similar features with adult livers, they aren’t perfect and our team still has work to do. For example, we still need to improve the capacity of the liver tissue to metabolize a variety of drugs. We also need to make it safer and more efficacious for eventual application in humans.[Deep knowledge, daily. Sign up for The Conversation’s newsletter.]Our study demonstrates the ability of these lab livers to mature and develop a functional network of blood vessels in just two and a half weeks. We believe this approach can pave the path for the manufacture of other organs with vasculature via genetic programming. The liver organoids provide several key features of an adult human liver such as production of key blood proteins and regulation of bile – a chemical important for digestion of food. When we implanted the lab-grown liver tissues into mice suffering from liver disease, it increased the life span. We named our organoids “designer organoids,” as they are generated via a genetic design. This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts. It was written by: Mo Ebrahimkhani, University of Pittsburgh. Read more: * Brain organoids help neuroscientists understand brain development, but aren’t perfect matches for real brains * Why are scientists trying to manufacture organs in space?Mo Ebrahimkhani receives funding from National Institute of Health, University of Pittsburgh and Arizona Biomedical Research Council.
This month, a collaboration between NASA and various research institutions pinpointed a “central biological hub” that controls health during space travel. The culprit is the cell’s energy factory, the mitochondria, which breaks down in function in a way eerily similar to aging. Like shutting down power and water in a city, disruptions to the mitochondria reverberate throughout the cells and organs, potentially leading to problems with sleeping, the immune system, and more in space. The results were [published in *Cell](https://www.cell.com/cell/fulltext/S0092-8674(20)31461-6).*
Microsoft Health-Tech Vision
Dr. James Weinstein, is Senior Vice President, Microsoft Healthcare, where he is in charge of leading strategy, innovation and health equity functions.
If you want to live long enough to see a reversal of aging and everlasting youth, exercise should be at the core of your routine.
Here I look at ten amazing benefits that exercise brings to your body and mind, so if you haven’t already got a regime on the go, hopefully this will convince you to start now.
Continue reading “Why We Should Exercise Regularly — Ten Amazing Benefits” »
Dr. Carolina Reis Oliveria, is the CEO and Co-Founder of OneSkin Technologies, a biotechnology platform dedicated to exploring longevity science.
Carolina holds her Ph.D. in Immunology at the Federal University of Minas Gerais, in collaboration with the Rutgers University, where she conducted research with pluripotent stem cells as a source of retinal pigmented epithelium (RPE) cells, as well as the potential of RPE-stem cells derived as toxicological models for screening of new drugs with intra-ocular applications.
